Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
2.
Ann Endocrinol (Paris) ; 80(1): 21-25, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29555080

RESUMO

The purpose of this study was to analyse the characteristics of 6 patients managed in a university hospital between 1996 and 2016 for non-islet cell tumor hypoglycemia (NICTH), a form of hypoglycaemia due to the paraneoplastic secretion of IGF-2 or its related substances. RESULTS: Three of these 6 patients (50%), aged over 69 years, including 2 with acromegaloid phenotype, presented with a pleural solitary fibrous tumor (SFT), with median diameter 20 cm (interquartile range, 12.5-20.5) with a low median SUV (3.3 g/mL (QR, 2-7.5)) on 18F-FDG PET. The other 3 patients presented respectively neuroendocrine carcinoma (NEC) of the palate (70-year-old woman), retroperitoneal myxofibrosarcoma (66-year-old man) and meningeal hemangiopericytoma (36-year-old woman). All 3 were inoperable and did not respond to any therapy other than glucose solution. Corticosteroid therapy was effective in the 3 SFTs and the NEC. One of the SFTs recurred 10 years later with asymptomatic hypoglycemia, which resolved after reintervention. Median (IQR) blood glucose levels of the 6 patients was 0.4g/L (QR, 0.31-0.41), with hypoinsulinemia at 0.7mIU/L (QR 0.7-2.0), undetectable GH, low IGF-1, normal IGF-2 level in 5/6 cases, a high IGF-2:IGF-1 ratio at 26.9 (QR, 20.8-37.8), hypokalemia and hypomagnesemia. CONCLUSION: NICTH is a rare syndrome, which should be considered in the presence of hypoinsulinemic hypoglycemia with low GH and IGF-1, and a IGF-2:IGF-1 ratio>10. Corticosteroid therapy was effective in elderly subjects, particularly with solitary fibrous tumor, which was generally operable. Hemangiopericytoma and myxofibrosarcoma had poor prognosis in younger patients.


Assuntos
Hipoglicemia/etiologia , Tumores Neuroendócrinos/complicações , Tumor Fibroso Solitário Pleural/complicações , Adulto , Idoso , Glicemia/análise , Feminino , Fibroma , Fibrossarcoma/sangue , Fibrossarcoma/complicações , Hemangiopericitoma/sangue , Hemangiopericitoma/complicações , Hospitais Universitários , Hormônio do Crescimento Humano/sangue , Humanos , Hipoglicemia/sangue , Hipoglicemia/tratamento farmacológico , Fator de Crescimento Insulin-Like I/análise , Fator de Crescimento Insulin-Like II/análise , Magnésio/sangue , Masculino , Neoplasias Meníngeas/sangue , Neoplasias Meníngeas/complicações , Tumores Neuroendócrinos/sangue , Potássio/sangue , Prognóstico , Neoplasias Retroperitoneais/sangue , Neoplasias Retroperitoneais/complicações , Tumor Fibroso Solitário Pleural/sangue
3.
Virchows Arch ; 472(3): 461-468, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29388012

RESUMO

Lymph node involvement (LNI) is one of the most important prognostic factors for poor survival in medullary thyroid carcinoma (MTC). At diagnosis, LNI is found in over 50% of sporadic MTCs, and especially in large tumours. Cervical lymph node dissection is therefore mandatory during MTC surgery. However, some large tumours (responsible for high preoperative basal calcitonin levels) are found to lack LNI, and can be cured definitely. Preoperative detection of these particular tumours might spare patients from undergoing extensive cervical dissection. The objective of the present retrospective study of a series of large sporadic MTCs was to identify clinical, biological and pathological factors that were predictive of LNI. Consecutive cases of large, sporadic MTCs (measuring at least 1 cm in diameter) were retrieved and reviewed. The levels of several mature microRNAs (miRs) in paraffin-embedded samples were assessed using qPCR. Of the 54 MTCs, 26 had LNI and 28 were pN0. Relative to pN0 patients, patients with LNI had a significant higher preoperative basal calcitonin level (p = 0.0074) and a greater prevalence of infiltrative margins (p < 0.0001), lymphovascular invasion (p = 0.0004), extrathyroidal extension (p < 0.0001), a higher pT stage (p = 0.0003) and more abundant desmoplastic stroma (p = 0.0006). Tumour expression levels of miR-21 (p = 0.0008) and miR-183 (p = 0.0096) were higher in the LNI group. The abundance of desmoplastic stroma (p = 0.007) and the miR-21 expression level (p = 0.0026) were independent prognostic factors for LNI. The abundance of desmoplastic stroma and high levels of miR-21 expression were strong indicators of LNI, and may thus help the surgeon to choose the extent of cervical lymph node dissection for large, sporadic MTCs with no preoperatively obvious LNI.


Assuntos
Carcinoma Medular/patologia , Carcinoma Neuroendócrino/patologia , Linfonodos/patologia , Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/patologia , Adulto , Idoso , Feminino , Humanos , Excisão de Linfonodo/métodos , Metástase Linfática/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
4.
Anal Bioanal Chem ; 409(14): 3677-3684, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28357482

RESUMO

Adding insulin directly into infusion bags seems to be a useful method for controlling hyperglycemia in patients under ternary parenteral nutrition (TPN). Its efficacy is assessed by glycemic monitoring but few data are available on insulin stability in this situation. Among the various methods for quantifying insulin levels in human serum, the immunoassay ones seemed potentially appropriate for a TPN admixture containing high lipid concentrations. We sought to identify and validate which of two immunoassay methods was the better to quantify human insulin and consequently be adapted to studying its stability in a TPN admixture. Two immunoassay methods to quantify recombinant human insulin were assessed in industrial TPN: an immunoradiometric assay (IRMA) and an immunoelectrochemiluminometric assay (IECMA). Validation trials for both methods were based on the accuracy profile method. Interference with immunometric assays due to the high lipidic content of TPN was eliminated through an improved preparation protocol using a bovine serum albumin (BSA) diluted in phosphate buffer saline (PBS). The relative total error of IECMA varied from 1.74 to 4.52% while it varied from -0.32 to 8.37% with IRMA. Only IECMA provided an accuracy profile with a 95% confidence interval of calculated-tolerance limits falling between the chosen acceptance limits (i.e., total error ≤±10%). IECMA combined with a BSA dilution is a simple and semi-automatic method that provides an accurate quantification of human insulin in a TPN admixture without any interference from lipids.


Assuntos
Hipoglicemiantes/sangue , Imunoensaio/métodos , Insulina/sangue , Nutrição Parenteral , Técnicas Eletroquímicas/métodos , Humanos , Hiperglicemia/sangue , Hiperglicemia/terapia , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Limite de Detecção , Nutrição Parenteral/métodos , Radioimunoensaio/métodos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/sangue
5.
Ann Biol Clin (Paris) ; 74(6): 669-679, 2016 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-27758762

RESUMO

Neuroendocrine tumors (NET) are rare heterogenous tumors which prevalence is increasing. Their features vary by anatomical location, functionality and hormonal production. Their management needs a multidisciplinary approach. Functional tumors develop characteristic clinical syndromes in contrast to non-functional tumors that are diagnosed fortuitously or at advanced stage. NET can secrete many specific and general biomarkers. CgA is the most sensitive general marker. Its value should be interpreted along with the renal function and the gastrin level. Some new biomarkers such as NTproBNP, proGRP and NET gene transcripts have been identified. The latter are not yet routine in clinical practice. We present In this review biological biomarkers involved in NET with a focus on the assays and their use in clinical practice.


Assuntos
Biomarcadores Tumorais , Tumores Neuroendócrinos/diagnóstico , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/fisiologia , Diagnóstico Diferencial , Técnicas de Diagnóstico Endócrino/normas , Humanos , Insulinoma/diagnóstico , Neoplasias Pancreáticas/diagnóstico , Síndromes Endócrinas Paraneoplásicas/diagnóstico , Padrões de Referência
6.
Ann Biol Clin (Paris) ; 74(1): 21-7, 2016.
Artigo em Francês | MEDLINE | ID: mdl-26711165

RESUMO

Thyroglobulin (Tg) is a high molecular weight glycoprotein located mainly in thyroid follicles, where thyroid hormones are synthesized and stored. In patients with differentiated thyroid cancer of follicular origin, serum Tg levels become undetectable following total thyroidectomy and iodine-131 remnant ablation. It is a key biomarker to follow-up patients with differentiated thyroid cancer, in combination with neck ultrasound monitoring. The measurement of Tg in the wash-out of the needle used for fine needle aspiration biopsy is a valuable aid to the diagnosis of lymph node metastasis. The presence of anti-thyroglobulin antibodies affects reliability of Tg results measured in serum or plasma. Systematic investigation of such antibodies is required to validate any Tg assay. Elevated or rising levels of anti-thyroglobulin antibodies can in turn be used as a surrogate tumor marker of thyroid cancer. The development of second-generation Tg assay (automated, highly sensitive) has enabled significant advances in the management of differentiated thyroid cancer: early detection of persistent or recurrent disease and follow-up care simplified in low-risk patients. Testing of serum Tg can also be useful in evaluating other clinical situations such as congenital hypothyroidism, endemic goiter and thyrotoxicosis factitia.


Assuntos
Adenocarcinoma/diagnóstico , Adenocarcinoma/terapia , Tireoglobulina/análise , Tireoglobulina/sangue , Testes de Função Tireóidea/tendências , Neoplasias da Glândula Tireoide/diagnóstico , Neoplasias da Glândula Tireoide/terapia , Adenocarcinoma/sangue , Adenocarcinoma/patologia , Autoanticorpos/análise , Autoanticorpos/sangue , Bioensaio/métodos , Bioensaio/normas , Bioensaio/tendências , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/sangue , Humanos , Monitorização Fisiológica/métodos , Prognóstico , Reprodutibilidade dos Testes , Testes de Função Tireóidea/métodos , Testes de Função Tireóidea/normas , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/patologia
7.
J Clin Endocrinol Metab ; 100(8): 2841-8, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26037512

RESUMO

CONTEXT: RTHα is a recently discovered resistance to thyroid hormone (RTH) due to mutation of THRA, the gene encoding TRα1, the thyroid hormone receptor. It has been described in a few patients with growth retardation, short stature, and a low free T4/free T3 (FT4/FT3) ratio. OBJECTIVE: A 27-year-old patient presenting with dwarfism and a low FT4/FT3 ratio was investigated. DESIGN: Clinical, biochemical, and radiological data were collected. Whole exome sequencing was performed in the patient and her relatives. RESULTS: The patient exhibited congenital macrocytic anemia and severe bone malformation with growth retardation, dwarfism, clavicular agenesis, and abnormalities of the fingers, toes, and elbow joints. In adulthood, she presented with active behavior, chronic motor diarrhea, and hypercalcemia. Treatment with T3 led to heart rate acceleration, worsening of diarrhea, and TSH suppression. Low resting energy expenditure normalized on T3. rT3, SHBG, and IGF-1 remained normal. A de novo monoallelic missense mutation in THRA was discovered, the N359Y amino acid substitution (c.1075A>T), which affected both the TRα1 and the non-receptor isoform TRα2. The mutant TRα1 had a decrease in transcriptional activity related to decreased T3 binding and a dominant-negative effect on the wild-type receptor. CONCLUSIONS: This patient presents a new phenotype including more significant bone abnormalities, lower TSH, and higher FT3 levels, without certainty of all her symptoms with the TRα1(N359Y) mutation. This case suggests that patients with a low FT4/FT3 ratio should be screened for THRA mutations, even if clinical and biological features differ from previous reported cases of RTHα.


Assuntos
Genes erbA , Mutação em Linhagem Germinativa , Síndrome da Resistência aos Hormônios Tireóideos/genética , Adulto , Substituição de Aminoácidos , Diarreia/complicações , Diarreia/genética , Nanismo/genética , Feminino , Humanos , Hipercalcemia/complicações , Hipercalcemia/genética , Anormalidades Musculoesqueléticas/genética , Fenótipo
8.
Eur Thyroid J ; 3(1): 60-4, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24847468

RESUMO

BACKGROUND: Coexistence of thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) with Graves' disease has been rarely reported. We describe a female patient displaying TSHoma with Graves' disease and who presented initially with inappropriate TSH values. CASE REPORT: A 36-year-old woman presented with signs of thyrotoxicosis, small and vascular goiter and mild bilateral exophthalmos. Thyroid function tests showed hyperthyroxinemia and normal TSH values despite the use of different assays. Heterophile antibody testing result was negative. The patient underwent total right lobectomy with partial left lobectomy after 18 months of carbimazole treatment. Histology confirmed Graves' disease. Symptoms of thyrotoxicosis recurred 2 months later. Thyroid function tests showed hyperthyroxinemia and elevated TSH values. Investigations were consistent with a 10-mm TSHoma. The patient underwent a trans-sphenoidal tumor resection following preoperative lanreotide preparation. Histological examination and immunocytochemistry concluded to a pure TSH-producing tumor. There was no evidence of tumor recurrence after 18 years of follow-up. CONCLUSION: Association of TSHoma with Graves' disease should be carefully taken into account, especially when TSH values are not compatible with either the clinical history or other thyroid functions tests.

9.
Ann Biol Clin (Paris) ; 72(1): 7-13, 2014.
Artigo em Francês | MEDLINE | ID: mdl-24492094

RESUMO

Pheochromocytomas and/or paragangliomas are rare, heterogeneous tumors of the chromaffin cells. Thirty percent of the patients presented with these diseases in a hereditary context. The biological diagnosis relies on the identification of excessive secretion of the metanephrines which are more sensitive and specific than those of catecholamines. The published recommendations give the opportunity to choose between the metanephrines in sera or urines. The concentrations of the free plasmatic metanephrines reflect the ongoing production of tumor. They are little sensitive to the renal failure. The gold standard method to measure the free metaphrines in plasma is the LC-MS/MS chromatography. This is the technical event that we use since 2008, and we relate our experience.


Assuntos
Neoplasias das Glândulas Suprarrenais/diagnóstico , Técnicas de Laboratório Clínico/métodos , Feocromocitoma/diagnóstico , Neoplasias das Glândulas Suprarrenais/epidemiologia , Neoplasias das Glândulas Suprarrenais/etiologia , Análise Química do Sangue , Catecolaminas/fisiologia , Técnicas de Laboratório Clínico/tendências , França/epidemiologia , Humanos , Paraganglioma/diagnóstico , Feocromocitoma/epidemiologia , Feocromocitoma/etiologia , Urinálise
10.
Endocr Relat Cancer ; 21(3): R105-20, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24351682

RESUMO

Well-differentiated neuroendocrine tumors (NETs) are a group of heterogeneous rare tumors. They are often slow-growing and patients can have very long survival, even at the metastatic stage. The evaluation of tumor progression and therapeutic responses is currently based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST) criteria. As for other malignancies, RECIST criteria are being reexamined for NETs in the era of targeted therapies because tumor response to targeted therapies is rarely associated with shrinkage, as opposed to prolonged progression-free survival. Therefore, size-based criteria no longer seem to be suitable to the assessment of NET progression and therapeutic responses, especially considering targeted therapies. New imaging criteria, combining morphological and functional techniques, have proven relevant for other malignancies treated with targeted therapies. To date, such studies have rarely been conducted on NETs. Moreover, optimizing the management of NET patients also requires considering clinical, biological, and pathological aspects of tumor evolution. Our objectives herein were to comprehensively review current knowledge on the assessment of tumor progression and early prediction of therapeutic responses and to broaden the outlook on well-differentiated NETs, in the era of targeted therapies.


Assuntos
Neoplasias Gastrointestinais/terapia , Terapia de Alvo Molecular , Tumores Neuroendócrinos/terapia , Animais , Progressão da Doença , Neoplasias Gastrointestinais/patologia , Humanos , Tumores Neuroendócrinos/patologia
11.
Presse Med ; 43(1): 40-56, 2014 Jan.
Artigo em Francês | MEDLINE | ID: mdl-24342177

RESUMO

TSH assay is the best parameter of the thyroid function. For adults, the normal interval of TSH concentrations range from 0.4 to 4 mUI/L. At the first trimester of pregnancy, TSH levels must be <2.5 mUI/L. Normal TSH levels increase with aging and obesity. The biological diagnosis relies on the identification of excessive secretion of the metanephrines which are more sensitive and specific than those of catecholamines. The concentrations of the free plasmatic metanephrines reflect the ongoing production of tumor. Plasma methoxytyramine is a novel biomarker of metastatic pheochromocytomas and paragangliomas. Serum IGF1 is a reliable measure of integrated GH concentrations in patients with acromegaly. Accurate assessment of IGF1 concentrations requires age and sex-matched control values. IGF1 is a sensitive tool for the diagnosis of acromegaly and efficacy of therapies. Serum AMH assay is more sensitive, more specific and more reproducible that counting of ovarian follicles by ultrasound. AMH level above 5 ng/mL (35 pmol/L) could be chosen as one of the diagnostic criteria for the polycystic ovary syndrome. In early or "incipiens" ovarian failure, the decrease in serum AMH is far ahead of the increase in FSH. Thyroglobulin (TG) and calcitonin (CT) are the sensitive and specific markers of respectively well-differentiated thyroid cancers of follicular origin and of the medullary thyroid cancers. The same tumour marker assay should be used to monitor a given patient. Chromogranin A (CgA) is a highly efficient biomarker for diagnosis and follow-up of various endocrine tumours. Despite the lack of international standardisation, some CgA assays are reliable.


Assuntos
Biomarcadores/sangue , Endocrinologia/métodos , Doenças da Glândula Tireoide/diagnóstico , Humanos
12.
Clin Biochem ; 46(13-14): 1305-8, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23628596

RESUMO

OBJECTIVES: We assessed the analytical performance of the TSH and FT4 assays on ADVIA Centaur in a multicenter national evaluation. DESIGN AND METHODS: A precision study and a method comparison were performed. Reference values stated by the manufacturer were checked from 379 normal subjects. RESULTS: For TSH and FT4, the intra-assay CVs were below 2.3 and 5.2%, respectively, and the inter-assay CVs below 4.4% and 7.2%, respectively. Therefore, the precision and reproducibility were acceptable. Bland-Altman bias plots revealed good correlation and agreement with Cobas assays. TSH and FT4 data yielded reference ranges of 0.64-3.24 mIU/L and 10.5-18.9 pmol/L, respectively. CONCLUSION: These assays demonstrate reliable characteristics. The reference ranges obtained can be used for interpretation of thyroid function.


Assuntos
Imunoensaio/instrumentação , Tireotropina/sangue , Tiroxina/sangue , Adolescente , Adulto , Idoso , Feminino , Humanos , Imunoensaio/normas , Medições Luminescentes/instrumentação , Masculino , Pessoa de Meia-Idade , Valores de Referência , Reprodutibilidade dos Testes , Testes de Função Tireóidea/instrumentação
13.
BMC Infect Dis ; 13: 159, 2013 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-23547830

RESUMO

BACKGROUND: Nosocomial infection diagnosis in the intensive care unit (ICU) remains a challenge. We compared routine measurements of procalcitonin (PCT), C-reactive protein (CRP), white blood cell count (WBC) and temperature in the detection of ICU-acquired infections. METHOD: Prospective observational cohort study in a University hospital Medicosurgical ICU. All patients admitted to the ICU ≥ 5 days (n = 141) were included into two groups, either infected (documented infection, n = 25) or non-infected (discharged from the ICU without diagnosis of infection, n = 88). RESULTS: PCT, CRP, WBC and temperature progression from day -4 (D-4) to day 0 (D0) (day of infection diagnosis or ICU discharge) was analysed. Differences (Δ) were calculated as D0 levels minus the lowest preceding value. D0 PCT and CRP were significantly increased in infected compared to non-infected patients (median, 1st and 3rd quartiles): 3.6 ng/mL (0.92-25) for PCT, 173 mg/L (126-188) for CRP versus 0.02 ng/mL (0.1-0.9) and 57 mg/mL (31-105) respectively (p < 0.0001). In multivariate analysis, D0 temperature > 38.6°C, PCT > 1.86 ng/mL, and CRP > 88 mg/L, performed well (AUCs of 0.88, 0.84, and 0.88 respectively). The sensitivity/specificity profiles of each marker (76%/94% for temperature, 68%/91% for PCT, and 92%/70% for CRP) led to a composite score (0.068 × D0 PCT + 0.005 × D0 CRP + 0.7 × temperature) more highly specific than each component (AUC of 0.90 and sensitivity/specificity of 80%/97%). CONCLUSION: Combining CRP, PCT and temperature is an approach which may increase of nosocomial infection detection in the ICU.


Assuntos
Temperatura Corporal , Proteína C-Reativa/metabolismo , Calcitonina/sangue , Infecção Hospitalar/diagnóstico , Precursores de Proteínas/sangue , Idoso , Biomarcadores/sangue , Peptídeo Relacionado com Gene de Calcitonina , Infecção Hospitalar/sangue , Feminino , Humanos , Unidades de Terapia Intensiva , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sensibilidade e Especificidade
15.
Presse Med ; 40(12 Pt 1): 1141-6, 2011 Dec.
Artigo em Francês | MEDLINE | ID: mdl-22035862

RESUMO

Calcitonin is the sensitive and specific marker of the medullary thyroid cancers. It is a diagnostic, pronostic and follow-up marker. Medullary thyroid cancer is a rare disease representing 4% of the thyroid cancers and occurring in 0.4% of nodular thyroid pathology. The use of sex specific adults normal ranges allows a better interpretation of the moderately elevated calcitonin levels. Hypercalcitoninaemia non due to medullary thyroid cancer are attributed mainly to male sex, tobacco use, overweight, renal failure and other endocrine tumors. CT is associated to carcinoembryonic antigen and possible procalcitonin assays. Calcitonin can be assayed in the wash-out fluid of the fine needle aspiration too. Stimulation tests give poor additional diagnostic information and are about to be abandoned.


Assuntos
Calcitonina/análise , Técnicas de Diagnóstico Endócrino/estatística & dados numéricos , Adulto , Algoritmos , Análise Química do Sangue/economia , Análise Química do Sangue/normas , Análise Química do Sangue/estatística & dados numéricos , Carcinoma Neuroendócrino , Interpretação Estatística de Dados , Técnicas de Diagnóstico Endócrino/economia , Técnicas de Diagnóstico Endócrino/normas , Feminino , Humanos , Masculino , Tumores Neuroendócrinos/sangue , Tumores Neuroendócrinos/diagnóstico , Padrões de Referência , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/diagnóstico , Nódulo da Glândula Tireoide/sangue , Nódulo da Glândula Tireoide/diagnóstico
16.
Int J Biol Markers ; 26(2): 94-101, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21574156

RESUMO

BACKGROUND: Multiple causes of false-positive chromogranin A (CgA) measurement have been reported that may affect its impact as a surrogate marker of RECIST progression in well-differentiated gastroenteropancreatic neuroendocrine tumors (WDGEPNET). ? AIMS: 1) To evaluate the frequency of false-positive CgA results. 2) To prospectively compare CgA variations with RECIST morphological changes in patients without known causes of false-positive CgA measurements.? METHODS: First, the conditions responsible for potentially false-positive CgA measurements were screened in 184 consecutive patients with metastatic WDGEPNET. Secondly, a variation in CgA at a 6-month interval was compared to RECIST results at 6 months in 46 patients.? RESULTS: Among 184 patients, elevated CgA was found in 130 cases (71%) including 99 patients with at least one cause of a false-positive result. Impaired kidney function as well as medication with proton pump inhibitors were found to be the 2 major causes of false-positive results. The sensitivity and specificity of CgA measurements compared with morphological tumor changes according to the RECIST criteria were 71% and 50%, respectively, at 6 months.? CONCLUSION: Routine screening for the causes of false-positive CgA measurements is mandatory in WDGEPNET patients. Our study does not validate the use of CgA as a surrogate marker of tumor progression.


Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Neuroendócrino/secundário , Cromogranina A/sangue , Neoplasias Gastrointestinais/patologia , Neoplasias Pancreáticas/patologia , Adulto , Idoso , Carcinoma Neuroendócrino/sangue , Reações Falso-Positivas , Feminino , Seguimentos , Neoplasias Gastrointestinais/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias , Neoplasias Pancreáticas/sangue
17.
Presse Med ; 40(2): e120-7, 2011 Feb.
Artigo em Francês | MEDLINE | ID: mdl-21036004

RESUMO

BACKGROUND: Primary hyperparathyroidism (PHPT) associates hypocalcemia and hypophosphatemia secondary to parathyroid hormone (PTH) excess. PHPT is asymptomatic for 80% of patients and responsible for a decrease in bone mineral density particularly in women. Vitamin D deficiency increases the risk of bone fractures. METHODS: We performed a prospective analysis of patients with PHPT in order to evaluate the prevalence of vitamin D deficiency. We determined the effects of vitamin D deficiency on bone metabolism: calcium, phosphate and PTH levels. We also analyzed biochemical markers of bone remodeling and bone mineral density (BMD) before and 6 months after vitamin D replacement. RESULTS: 75 patients with PHPT were identified: 38 patients with vitamin D deficiency but only 22 patients could be followed (G1). 14 patients with a normal level of vitamin D were followed (G2). Prevalence of vitamin D deficiency was 51%. Calcium and phosphate levels were similar into both groups. PTH levels were higher in the G1 group. Calciuria was significantly lower in the G1. For markers of bone formation (fragments of collagen CTX and alkaline phosphatase): osteocalcine levels were higher in G1 group. For bone resorption: télopeptides levels were significantly higher in the G1 group. T score was significantly lower in this group, favoring a significant osseous attack. After 6 months of substitution with vitamin D, calcium decreased and hypophosphatemia normalized. PTH levels decreased (-50.7%). Calciuria increased without risks of urinary lithiasis. Bone mineral density loss decreased while markers of bone turn over increased. DISCUSSION: Vitamin D deficiency increases the risk of bone fragility in PHPT. Few data are available in France concerning the prevalence of vitamin D deficiency in PHPT. Our results were similar to data in other countries. Vitamin D replacement with regular monitoring of calcium and calciuria levels is beneficial for metabolic and hormonal status, improves bone density, without systematic opposing effects. The follow-up of effectiveness by BMD could be associated with measurement of markers of bone remodeling. CONCLUSION: In asymptomatic PHPT, particularly those for which surgery is not indicated, measurement of 25 OH Vitamin D should be systematic. It is recommended before surgery.


Assuntos
Doenças Ósseas/etiologia , Hiperparatireoidismo Primário/complicações , Deficiência de Vitamina D/complicações , Idoso , Feminino , Humanos , Masculino , Prevalência , Estudos Prospectivos , Índice de Gravidade de Doença , Deficiência de Vitamina D/epidemiologia
18.
Presse Med ; 40(1 Pt 1): e1-8, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21036005

RESUMO

OBJECTIVE: Hypothyroidism can occur after radioiodine treatment for Graves' disease. It may happen precociously and transiently in the first year after treatment. The purpose of this study was to understand the mechanisms responsible for precocious hypothyroidism. METHODS: 36 patients treated for Graves disease by radiodiodine were prospectively studied; The following variables were included in the analysis: age, gender, attendance for Graves' orbitopathy (GO), delay before radioiodine treatment, number of recurrences, previous treatments, corticosteroid therapy, thyroid mass, and (131)I dose. The titres of free T4 (FT4), thyroid-stimulating hormone (TSH), anti-TSH receptor antibodies (TRAb), anti-thyroid peroxydase antibodies (TPOAb) and anti-thyroglobulin antibodies (TGAb) were monitored. Thyroid stimulating (TSAb) and blocking (TBAb) antibodies were determined and (123)I uptake was measured when hypothyroidism occurred. RESULTS: 23 patients became precociously hypothyroid (group A) while 13 patients did not (group B). The initial TGAb titre was higher in group A (p=0.0024), and corticosteroid therapy was used more frequently to avoid aggravating GO in group B (p=0.0276). TPOAb and TGAb titres increased significantly only in group A (p=0.0112 and p=0.0202, respectively). When hypothyroidism occurred, TBAb was present in 13 patients. Transient hypothyroidism due to TBAb was observed in 1 patient. No iodide organification impairment was disclosed by the perchlorate test. CONCLUSION: Radioinduced thyroiditis appears to be the main mechanism involved in the pathogenesis of precocious hypothyroidism. A higher TGAb titre before treatment is associated with precocious hypothyroidism, suggesting the prognostic value of TGAb. Transient hypothyroidism directly due to TBAb remains rare.


Assuntos
Doença de Graves/radioterapia , Hipotireoidismo/etiologia , Radioisótopos do Iodo/efeitos adversos , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Tempo
20.
Surgery ; 146(6): 986-92, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19958924

RESUMO

BACKGROUND: Operative excision of abdominal extra-adrenal paragangliomas (EAPs) does not preclude the late development of local-regional recurrence. We describe the incidence, characteristics, and outcome of this rarely reported feature. METHODS: Retrospective analysis of local-regional recurrence that occurred during follow-up of 51 consecutive patients operated for a sporadic (n = 26) or hereditary (n = 25) EAP. RESULTS: Seven patients with a sporadic or syndromic EAP (n = 4: von Hippel-Lindau syndrome and SDHB, SDHC, and SDHD gene mutations) underwent reoperation for a local-regional recurrence after a median time of 46 months (interquartile range [IQR], 16-100). The Kaplan-Meier estimated incidence of local-regional recurrence (+/- standard error of the mean) reached 15% +/- 7% at 5 years and 23% +/- 9% after 10 years. Recurrent EAPs were all secreting and 38% provoked clinical symptoms. New lesions were smaller than the primary EAP (P = .01) and more often associated with lymph node metastases (43% vs 4%, P = .01). Operative excision seemed complete in 5 patients. Clinical remission was maintained in 4 patients after a median follow-up of 57 months (IQR, 22-102). CONCLUSION: Local-regional recurrence of sporadic and syndromic EAPs is frequent and may be delayed beyond 10 years, requiring lifelong follow-up after the initial operation. When technically feasible, operative excision can lead to prolonged remission.


Assuntos
Recidiva Local de Neoplasia/etiologia , Paraganglioma Extrassuprarrenal/etiologia , Adulto , Feminino , Humanos , Metástase Linfática , Masculino , Proteínas de Membrana/genética , Pessoa de Meia-Idade , Mutação , Recidiva Local de Neoplasia/genética , Recidiva Local de Neoplasia/cirurgia , Paraganglioma Extrassuprarrenal/genética , Paraganglioma Extrassuprarrenal/secundário , Paraganglioma Extrassuprarrenal/cirurgia , Prognóstico , Reoperação , Estudos Retrospectivos , Succinato Desidrogenase/genética , Síndrome , Proteína Supressora de Tumor Von Hippel-Lindau/genética , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA